Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
642,643

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 5:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Align Technology (ALGN) Lags Q3 Earnings and Revenue Estimates

Align Technology (ALGN) delivered earnings and revenue surprises of -5.31% and 3.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.

Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align (ALGN) Gains From New Launches, Strategic Partnerships

Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.

Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?

Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Add Cencora (COR) to Your Portfolio Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

STERIS' (STE) Improved Volume, New Buyouts Drive Growth

On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.

PetMeds (PETS) to Advance Pet Care With New Collaboration

PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.

Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft

Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.

Here's Why You Should Invest in Insulet (PODD) Stock for Now

Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.

Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?

Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

Here is how Align Technology (ALGN) and Artivion (AORT) have performed compared to their sector so far this year.

Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

Investors continue to be optimistic about Thermo Fisher (TMO) due to its impressive acquisition deals and end-market strength.

Here's Why You Should Retain Fresenius Medical (FMS) for Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi

Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.

Teleflex (TFX) Advances Urology Portfolio With New Buyout

Teleflex's (TFX) recent buyout is in line with its strategy of acquiring assets that accelerate the rate of expansion.

Globus Medical (GMED) Gains From NuVasive Buyout, Innovation

Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Labcorp (LH) Launches Biomarker Test for Alzheimer's Disease

Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.

Nalak Das headshot

5 Large-Cap Stocks to Buy on the Dip for Q4 2023

We have narrowed our search to five large-cap (market capital > $10 billion) stocks with attractive valuations. These stocks are: TWLO, KDP, ULTA, ALGN, ZBH.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Fresenius Medical (FMS) Sinks on Potential Rise in Competition

Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.